PURPOSE: Aberrant overexpression of growth factor receptor-bound protein 7 (GRB7) and its variant GRB7v has been found in numerous human cancers. The goal of this study was to characterize the functions of GRB7 and GRB7v in the ovarian carcinogenesis and to investigate the differential roles of GRB7 and GRB7v in the modulation of signaling pathways. EXPERIMENTAL DESIGN: Quantitative reverse transcription-PCR, Western blot, and immunohistochemical analyses were used to evaluate the levels of GRB7 and GRB7v. The cellular localization, functions, and signaling pathways regulated by GRB7 and GRB7v were investigated by enforced expression of GRB7 and GRB7v. RESULTS: Quantitative reverse transcription-PCR and Western blot analyses showed that GRB7 and GRB7v were frequently upregulated in ovarian cancer samples. The overexpressed GRB7 (P = 0.009) and GRB7v (P = 0.017) were significantly correlated with high-grade ovarian cancer. Immunohistochemical analysis on ovarian cancer tissue array confirmed that the upregulated GRB7 was significantly correlated with high-grade ovarian cancer (P = 0.001). Confocal microscopy analysis showed that GRB7 and GRB7v predominately localized in cytoplasm of ovarian cancer cells, consistent with their roles as signaling adaptors. Enforced expression of GRB7 promoted cell proliferation, migration, and invasion, whereas GRB7v only increased cell proliferation and anchorage-independent growth ability. With the treatment of specific kinase inhibitors, we showed that both GRB7 and GRB7v promoted cell proliferation through activating extracellular signal-regulated kinase signaling, whereas GRB7 enhanced cell migration/invasion by activating c-Jun NH(2) terminal kinase signaling. CONCLUSIONS: Our studies implicate that the overexpressed GRB7 and GRB7v are associated with high-grade tumors and exert distinct tumorigenic functions through regulating different signaling pathways in ovarian cancer cells. Copyright 2010 AACR.
PURPOSE: Aberrant overexpression of growth factor receptor-bound protein 7 (GRB7) and its variant GRB7v has been found in numerous human cancers. The goal of this study was to characterize the functions of GRB7 and GRB7v in the ovarian carcinogenesis and to investigate the differential roles of GRB7 and GRB7v in the modulation of signaling pathways. EXPERIMENTAL DESIGN: Quantitative reverse transcription-PCR, Western blot, and immunohistochemical analyses were used to evaluate the levels of GRB7 and GRB7v. The cellular localization, functions, and signaling pathways regulated by GRB7 and GRB7v were investigated by enforced expression of GRB7 and GRB7v. RESULTS: Quantitative reverse transcription-PCR and Western blot analyses showed that GRB7 and GRB7v were frequently upregulated in ovarian cancer samples. The overexpressed GRB7 (P = 0.009) and GRB7v (P = 0.017) were significantly correlated with high-grade ovarian cancer. Immunohistochemical analysis on ovarian cancer tissue array confirmed that the upregulated GRB7 was significantly correlated with high-grade ovarian cancer (P = 0.001). Confocal microscopy analysis showed that GRB7 and GRB7v predominately localized in cytoplasm of ovarian cancer cells, consistent with their roles as signaling adaptors. Enforced expression of GRB7 promoted cell proliferation, migration, and invasion, whereas GRB7v only increased cell proliferation and anchorage-independent growth ability. With the treatment of specific kinase inhibitors, we showed that both GRB7 and GRB7v promoted cell proliferation through activating extracellular signal-regulated kinase signaling, whereas GRB7 enhanced cell migration/invasion by activating c-Jun NH(2) terminal kinase signaling. CONCLUSIONS: Our studies implicate that the overexpressed GRB7 and GRB7v are associated with high-grade tumors and exert distinct tumorigenic functions through regulating different signaling pathways in ovarian cancer cells. Copyright 2010 AACR.
Authors: Tabitha A Peterson; Renee L Benallie; Andrew M Bradford; Sally C Pias; Jaron Yazzie; Siamee N Lor; Zachary M Haulsee; Chad K Park; Dennis L Johnson; Larry R Rohrschneider; Anne Spuches; Barbara A Lyons Journal: J Mol Recognit Date: 2012-08 Impact factor: 2.137
Authors: Cai Feng Dai; Yi Zhou Jiang; Yan Li; Kai Wang; Pei Shu Liu; Manish S Patankar; Jing Zheng Journal: Histochem Cell Biol Date: 2011-04-05 Impact factor: 4.304
Authors: Prakash Paudyal; Sanjay Shrestha; Thushara Madanayake; Charles B Shuster; Larry R Rohrschneider; Aaron Rowland; Barbara A Lyons Journal: J Mol Recognit Date: 2013-11 Impact factor: 2.137
Authors: Michalina Janiszewska; Shayna Stein; Otto Metzger Filho; Jennifer Eng; Natalie L Kingston; Nicholas W Harper; Inga H Rye; Maša Alečković; Anne Trinh; Katherine C Murphy; Elisabetta Marangoni; Simona Cristea; Benjamin Oakes; Eric P Winer; Ian E Krop; Hege G Russnes; Paul T Spellman; Elmar Bucher; Zhi Hu; Koei Chin; Joe W Gray; Franziska Michor; Kornelia Polyak Journal: JCI Insight Date: 2021-06-08
Authors: David W Chan; Winnie W Y Hui; Patty C H Cai; Michelle X Liu; Mingo M H Yung; Celia S L Mak; Thomas H Y Leung; Karen K L Chan; Hextan Y S Ngan Journal: PLoS One Date: 2012-12-20 Impact factor: 3.240
Authors: Thomas X Lu; Eun-Jin Lim; Svetlana Itskovich; John A Besse; Andrew J Plassard; Melissa K Mingler; Joelle A Rothenberg; Patricia C Fulkerson; Bruce J Aronow; Marc E Rothenberg Journal: PLoS One Date: 2013-03-22 Impact factor: 3.240